ARTICLE | Company News

Trimeris, Novartis, Roche deal

October 11, 2010 7:00 AM UTC

Trimeris will no longer be responsible for $18.7 million owed to Roche related to marketing expenses for Fuzeon enfuvirtide as part of an amended 1999 deal in which the companies were developing the viral fusion inhibitor peptide analog based on HIV gp41 to treat HIV infection (see BioCentury, July 19, 1999). ...